Development of effective targeted cancer therapeutics depends upon distinguishing disease-associated âdriverâ mutations, which play causative roles in malignancy pathogenesis, from âpassengerâ
Dormant chemotherapy-resistant leukemia cells can survive for an extended period before relapse. Nevertheless, the mechanisms underlying the development of chemoresistance in vivo remain unclear. Usin
